Gout in Aotearoa New Zealand: the equity crisis continues in plain sight
- PMID: 30408813
Gout in Aotearoa New Zealand: the equity crisis continues in plain sight
Conflict of interest statement
Dr Dalbeth has received speaking fees from Pfizer, Horizon, Janssen and AbbVie, consulting fees from Horizon and Kowa, and research funding from Amgen and AstraZeneca, and is currently principal investigator on a clinical trial of intensive urate-lowering therapy (funded by the Health Research Council of New Zealand). Within the last five years, she has been principal investigator on a clinical trial of febuxostat in early gout, and received consulting or speaking fees from Takeda, Menarini, and Teijin.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical